Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Phase 3 Recruiting
304 enrolled
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
Krascendo 2
Phase 3 Recruiting
600 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
REZILIENT4
Phase 3 Recruiting
360 enrolled
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Phase 3 Recruiting
474 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Recruiting
538 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
NeoCOAST-2
Phase 2 Recruiting
630 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1 Recruiting
19 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
Phase 2 Recruiting
51 enrolled
MK-3475-01G
Phase 2 Recruiting
90 enrolled
HyDose
Phase NA Recruiting
87 enrolled
HARMONIC
Phase 2 Recruiting
90 enrolled
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Phase 2 Recruiting
112 enrolled
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Phase 2 Recruiting
60 enrolled
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
Phase 2 Recruiting
27 enrolled
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Phase 2 Recruiting
82 enrolled
NEOpredict-EGF
Phase 2 Recruiting
20 enrolled
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Phase 1 Recruiting
28 enrolled
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Phase 2 Recruiting
280 enrolled
NIBCUN
Phase 2 Recruiting
36 enrolled
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Phase 1/2 Recruiting
25 enrolled
BECOME
Phase 3 Recruiting
12,000 enrolled
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
Recruiting
64 enrolled
ATATcH Alternating Treatment Plans for Advanced Cancer
Phase 2 Recruiting
150 enrolled